Ацетилцистеин

Quick links

Choose a section

Quick links to important sections

Advertisements

Ацетилцистеин

Advertisements
Advertisements

Overview of Ацетилцистеин

Quick Facts

Property Description
Active ingredient Acetylcysteine (N-acetyl-L-cysteine, NAC)
Form Effervescent tablets, oral solution, solution for inhalation, solution for injection
Pharmacological class Mucolytic agent, Antidote, Antioxidant
General Purpose Facilitates mucus clearance and supports cellular defense
Origin Synthetic derivative of L-cysteine

What is Ацетилцистеин?

Ацетилцистеин is a pharmaceutical substance used primarily for its ability to modify and thin thick bodily secretions and as a vital component in certain detoxification protocols. The drug entity is known by its International Nonproprietary Name (INN), Acetylcysteine, and the chemical abbreviation NAC (N-acetyl-L-cysteine).


What Type of Medicine is Ацетилцистеин (Acetylcysteine)?

Ацетилцистеин is classified as a synthetic pharmaceutical substance that functions as a highly effective mucolytic agent and is also indispensable as a specific antidote. The substance is chemically synthesized as a stable derivative of the naturally occurring amino acid, L-cysteine. This unique chemical structure establishes its core pharmacological classification, granting it the ability to chemically reduce the viscosity of secretions, while its role as an antidote highlights its capacity to support the body’s detoxification processes. Acetylcysteine is included on the Model List of Essential Medicines, a distinction clinically recognized for its essential and verified utility in certain indications.


Understanding the General Purpose of Acetylcysteine

The general purpose of Acetylcysteine is twofold: to facilitate the clearance of sticky secretions and to support the body’s essential antioxidant defenses. The drug’s mechanism allows it to break down the dense internal structure of thick, tenacious mucus, resulting in secretions that are easier to expel from the respiratory tract. Furthermore, Acetylcysteine acts as a crucial precursor that the body uses to synthesize glutathione (GSH), which helps the body neutralize damaging reactive oxygen species. This capability means the medicine helps boost the body's natural defense against cellular damage and oxidative stress. For example, Acetylcysteine is typically used when an accumulation of thick secretions, often associated with various respiratory conditions, needs to be rapidly addressed.


Common Forms and Administration Types

Acetylcysteine is produced in various pharmaceutical preparations to ensure suitability for different therapeutic needs, including effervescent tablets, oral solution, solution for inhalation, and solution for injection. This INN is widely used, and popular examples of formulations containing this active ingredient include the brands АЦЦ (ACC) and Флуимуцил (Fluimucil). These diverse product forms allow the medicine to be administered through the oral route for systemic or digestive tract effects, via inhalation for targeted action in the airways, or intravenously for rapid systemic effects, particularly in urgent or critical care settings.

Regulatory References

  1. World Health Organization
Advertisements

What side effects are possible with Ацетилцистеин?

Possible side effects and safety information

The officially documented safety profile of Acetylcysteine details adverse reactions based on their frequency and the system-organ classes affected, as classified in regulatory documents.


Frequency-Classified Adverse Reactions

The most frequently reported non-serious effects are categorized as uncommon (affecting up to 1 in 100 people) and primarily involve Gastrointestinal disorders (e.g., nausea, vomiting, abdominal pain, diarrhea) and Skin and subcutaneous tissue disorders (e.g., rash, urticaria, pruritus). Other uncommon effects include headache, fever, and tachycardia. Rare effects (affecting up to 1 in 1,000 people) include bronchospasm and dyspnoea.


Serious Adverse Reactions and Safety Constraints

The regulatory label documents the potential for very rare (affecting fewer than 1 in 10,000 people) but serious adverse reactions, including anaphylactic shock and haemorrhage (bleeding). Severe cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN), have also been reported in temporal association with use.

Safety notes specify caution for certain patient populations. Individuals with bronchial asthma require close monitoring due to the risk of bronchospasm. Caution is also advised for patients with a history of peptic ulcers due to the potential risk of upper gastrointestinal haemorrhage. For intravenous administration, low-weight patients, especially children, carry a documented risk of fluid overload.

Time-related patterns note that anaphylactoid reactions are typically observed soon after the start of intravenous infusion, and for mucolytic use, an increase in bronchial secretion volume may occur at the beginning of treatment. The medicine is strictly contraindicated in cases of known hypersensitivity to the substance.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the Acetylcysteine overdose profile based on documented clinical manifestations, required emergency actions, and specific population risks.

Documented Manifestations and Severe Outcomes

Over-exposure may initially present with common gastrointestinal symptoms such as nausea, vomiting, and diarrhoea. Regulatory labeling also documents the risk of more serious, acute systemic reactions, particularly with high-dose intravenous use. These reactions, classified as anaphylactoid symptoms, can involve rash, facial flushing, bronchospasm, and circulatory changes like hypotension and tachycardia. The most severe documented outcomes are linked to risks of fluid overload, hyponatraemia (low blood sodium), and associated risks such as seizure. Acute toxicity is also officially associated with acute renal failure and, rarely, can be fatal. The risk of complications is specifically noted as higher in children or patients weighing less than 40 kg.

Required Emergency Actions

The official guidance mandates specific actions when a serious reaction or overdose is suspected:

  • Immediate Medical Advice: Must be sought immediately if new cutaneous or mucosal alterations (such as a widespread rash or swelling) are observed.
  • Urgent Discontinuation: The medicine must be discontinued immediately upon the suspicion of a serious reaction, as instructed by the regulator.
  • Management: The treatment for Acetylcysteine overdose is defined as symptomatic and supportive. No specific antidote for the medicine itself is known. Continuous monitoring of renal, hepatic, and electrolyte function may be required in a hospital setting.
Advertisements

Therapeutic Uses of Ацетилцистеин

What Ацетилцистеин Treats: Main Uses and Benefits

Relief for Viscid Respiratory Congestion

This medication is commonly used to help manage symptoms related to physical discomfort from thick, tenacious, and abnormal mucus accumulation in the respiratory tract. Acetylcysteine is utilized in conditions characterized by abnormal, viscid, or inspissated mucous secretions, which includes pneumonia, chronic bronchitis, and Cystic Fibrosis. It provides the key benefit of liquefying and thinning these secretions, making them easier to expel, which may assist with easing the symptom load of chest congestion and contributes to improved comfort during symptomatic periods. This use is relevant when supportive symptom management is appropriate.


Quick Fact: Relief for Thick Mucus

Property Description
Primary Indication Category Mucolytic Support (Respiratory)
Targeted Symptoms Thick, sticky, or tenacious sputum
Core Benefit Easier expectoration and symptomatic comfort

Critical Support and Organ Protection

Acetylcysteine plays a role in managing the acute systemic imbalance associated with drug toxicity, particularly in clinical settings that involve acute or unstable symptom patterns related to drug toxicity. This application is relevant in contexts involving heightened systemic burden. The primary benefit is in supporting the body's processes to help address the risk of severe liver injury (hepatotoxicity), offering supportive relief when symptoms become more noticeable in this urgent clinical setting. The supportive use of the medication is also relevant in contexts involving heightened systemic burden, such as when symptoms are linked to organ-specific functional stress.

Regulatory References

  1. NIH StatPearls - N-Acetylcysteine
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Acetylcysteine? Official Regulatory Information

The eligibility to use Acetylcysteine is strictly defined by regulatory authorities and often depends on whether the medicine is used as a mucolytic or as an antidote.

Contraindicated and Restricted Populations

Classification Population/Condition
Contraindicated Individuals with known hypersensitivity to Acetylcysteine or its excipients. Also, patients with hereditary fructose intolerance if the specific oral product contains sorbitol.
Conditional Use Patients with bronchial asthma or a history of peptic ulcers/esophageal varices require close monitoring due to specific labeled risks.

Age and Physiological Status Eligibility

Population Group Regulatory Status
Children under 2 years (Mucolytic) Not recommended due to the risk of inability to expel liquefied secretions.
All Ages (Antidote Use) Permitted and established for the treatment of acetaminophen overdose, including use in neonates and infants.
Pregnancy/Lactation (General Use) Restricted; use is generally not recommended unless clearly needed, as insufficient data exists.

Eligibility is defined by mandatory exclusions and conditional use rules based on patient health status and the context of the medication's intended use, as documented in official prescribing information.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Acetylcysteine details specific interaction patterns concerning co-administration with other substances and product components.

Pharmacodynamic Restrictions

The combination of Acetylcysteine and antitussive medicinal products is formally prohibited. This restriction is necessary to prevent the risk of accumulated bronchial secretions due to the concurrent suppression of the cough reflex. Co-administration with Nitroglycerin or other nitrates may result in a potentiation of vasodilatory effects, leading to a risk of significant hypotension.

Exposure and Timing Constraints

To avoid a reduction in efficacy resulting from in vitro inactivation, oral antibiotics (such as cephalosporins or tetracyclines) must be administered at least two hours before or two hours after Acetylcysteine. Acetylcysteine’s chelating effect on certain heavy metal salts (e.g., iron, gold) requires a temporal separation of doses to prevent reduced bioavailability of the salt. Furthermore, Activated Charcoal can reduce Acetylcysteine's absorption, a key consideration during antidote use. Co-administration with Carbamazepine may result in sub-therapeutic plasma levels of the latter.

Excipient-Based Notes

Caution is formally advised for patients with a history of peptic ulcer when co-administering with other gastrointestinal irritants. Specific formulations containing Aspartame or Sorbitol are restricted for use in patients with Phenylketonuria or hereditary fructose intolerance, respectively.

Advertisements

Mechanism of Action

How Ацетилцистеин Works

The mechanism of action for Ацетилцистеин (Acetylcysteine, NAC) is rooted in its unique chemistry, providing a highly reactive thiol group that facilitates three distinct, yet complementary, biological actions: mucolysis, antioxidant precursor activity, and anti-inflammatory modulation.


Direct Chemical Cleavage of Secretions

This domain involves the drug acting as a reducing agent that targets and cleaves the disulfide bonds (S-S) cross-linking the mucin protein polymers. This direct chemical action structurally breaks down high-molecular-weight mucus, reducing its viscosity and elasticity. This physiological change facilitates the function of the mucociliary transport system through the alteration of secretion consistency.


️ Precursor for Glutathione Synthesis

Acetylcysteine is rapidly deacetylated to L-cysteine, which acts as the rate-limiting precursor required for the synthesis and replenishment of a primary endogenous antioxidant, Glutathione (GSH). This replenishing mechanism boosts the intracellular redox buffer, influencing cellular defense capacity against damaging Reactive Oxygen Species (ROS) and participating in the conjugation pathway essential for neutralizing hepatic electrophilic metabolites.


Modulation of Oxidative Stress Pathways

Beyond replenishment, the thiol group acts as a direct scavenger of free radicals, readily neutralizing oxidative compounds protecting cellular components from oxidative reactions. Additionally, by modulating the overall cellular redox environment, the drug can inhibit the activation of inflammatory transcription factors, such as NF-kappaB, which modulates the downstream release of pro-inflammatory mediators.

Advertisements

Dosage and Administration Information

Acetylcysteine administration is strictly defined by its clinical context and delivery method, utilizing routes such as oral, inhalation, direct instillation, and intravenous (IV) infusion. The dosing schedule differs based on the intent of use, following two distinct clinical frameworks.

For mucolytic support, administration typically involves intermittent, fixed doses, such as 200 mg taken two to three times daily, or a single daily dose of 600 mg. Oral formulations like effervescent tablets must be fully dissolved in a glass of water prior to consumption, usually recommended after meals. Inhaled administration, intended for localized action, uses specified concentrations (10% or 20% solutions) nebulized multiple times per day.

The use of Acetylcysteine as an antidote involves highly specific, time-dependent regimens in supervised settings. The oral antidotal regimen begins with a 140 mg/kg loading dose, followed by 17 maintenance doses of 70 mg/kg taken every four hours. The IV protocol consists of a total 300 mg/kg dose delivered through three sequential infusions over a continuous 21-hour period. For intravenous use, the concentrated solution must be diluted in compatible fluids (like 5% Glucose) before administration. Special procedural rules exist for specific populations; for instance, the IV dose for obese patients is calculated using a maximum weight of 110 kg, and pediatric IV administration requires fluid volume adjustment to mitigate risks.

Advertisements

Recent Clinical Evidence

Ацетилцистеин: Recent Clinical Evidence

N-acetylcysteine (NAC) is widely researched for its primary roles as a mucolytic agent and as a specific antidote for acetaminophen (paracetamol) overdose. Its therapeutic utility is primarily driven by its ability to replenish stores of glutathione (GSH), the body's main antioxidant, and its capacity to break down disulfide bonds in mucus proteins.


Respiratory Conditions

In respiratory conditions characterized by excessive or thick mucus, such as chronic bronchitis and Chronic Obstructive Pulmonary Disease (COPD), NAC is used to help reduce mucus viscosity and facilitate clearance. Studies, including meta-analyses, have examined the effect of long-term NAC use on disease progression. Specifically:

  • Exacerbation Rate: Research has explored the relationship between prolonged oral NAC administration and a reduced rate of exacerbations (periods of acute worsening of symptoms) in certain patients with COPD and chronic bronchitis.
  • Mucus Regulation: NAC's mucolytic action is well-established; its use has been evaluated for its potential to also influence mucus secretion and inflammatory markers in the airways.

Other Areas of Investigation

Beyond its established uses, ongoing clinical research continues to investigate NAC's potential utility in other conditions, based on its broad antioxidant and anti-inflammatory properties:

Research Focus Area Status of Evidence
Acetaminophen Toxicity Established clinical standard of care.
Psychiatric Conditions Evidence remains limited, but research is ongoing in areas like bipolar disorder and obsessive-compulsive disorder.
Non-Acetaminophen Liver Injury Some guidelines suggest potential benefit, but clinical evidence is minimal and not conclusive.

The safety profile of NAC is generally considered favorable, with common side effects typically involving the gastrointestinal tract, and is a factor in its continued investigation across various chronic conditions.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ацетилцистеин (FAQ)


Q: Is Ацетилцистеин considered a cough medicine or a mucus thinner?

According to official product information, Acetylcysteine is primarily classified as a mucolytic. This means its intended function is to make thick, viscous mucus secretions thinner and easier to clear from the airways.

Q: Why is Ацетилцистеин used for reasons other than cough or respiratory problems?

Beyond its use for respiratory support, Acetylcysteine is also used in a highly specialized, supervised setting as an antidote. This specialized application is used to help prevent or lessen potential liver damage that can follow an overdose of acetaminophen.

Q: What are the official, approved uses for Ацетилцистеин?

Regulatory documents define the main uses of this drug as twofold. It is used for mucolytic therapy to treat conditions involving excessive mucus, and it is also approved for use as an antidote in acetaminophen overdose protocols.

Q: What are the most frequently reported side effects of Ацетилцистеин?

Official reports indicate that the most common adverse effects are related to the gastrointestinal tract, frequently including nausea and vomiting. Additionally, signs of hypersensitivity, such as a rash or flushing, are sometimes reported.

Q: Is it common to feel nauseous or have stomach discomfort after taking it?

Yes, nausea and vomiting are explicitly listed among the common adverse reactions documented in regulatory information. These types of gastrointestinal issues are among the most frequently observed side effects in clinical reports.

Q: Can Ацетилцистеин cause an increase in coughing initially?

Official records note the reporting of respiratory symptoms, including an increase in coughing, but do not offer interpretation regarding the initial increase in cough.

Q: Does Ацетилцистеин cause drowsiness or affect alertness?

Regulatory records of adverse events have noted drowsiness in some reports. However, the exact frequency of this effect is often not specified in the official information.

Q: What are the signs of a serious or allergic reaction to Ацетилцистеин?

Signs of a serious reaction, referred to as an anaphylactoid reaction, can include rash, wheezing, shortness of breath, and a drop in blood pressure (hypotension). Symptoms like these are defined in regulatory documents as signs of a serious reaction.

Q: What is the guidance on combining Ацетилцистеин with nitroglycerin products?

Regulatory warnings state that Acetylcysteine may potentiate the vasodilatory effect of nitroglycerin, meaning it could increase the effect of blood vessel widening. Official product information advises that caution and blood pressure monitoring may be necessary when these two medicines are used together.

Q: Are there specific foods or beverages that interact with Ацетилцистеин absorption?

Official administration instructions often recommend taking the oral form, such as effervescent tablets, after a meal. Regulatory information notes this recommendation for administration, but does not detail specific food-drug interactions.

Q: What are the known contraindications listed in official documents for Ацетилцистеин?

The primary condition that prevents the use of Acetylcysteine, according to official documents, is a known hypersensitivity to the active substance or to any of the ingredients in its formulation.

Q: What is the official guidance on using Ацетилцистеин during pregnancy or breastfeeding?

Official guidance indicates that human data on use during pregnancy is limited. Official documents state that its use is generally not recommended unless clearly needed, due to limited human data.

Q: Is Ацетилцистеин generally considered suitable for children?

Regulatory information specifies that for its mucolytic use, the drug is contraindicated in children under the age of two years in some official product information. This is an important age restriction noted in some product labels.

Q: What are the official age restrictions for different formulations of Ацетилцистеин?

For its mucolytic use, the main age restriction noted in regulatory documents is that the drug is contraindicated for use in children below two years old across certain formulations. Use in other populations is determined by specific indications and dosage.

Q: Can people with conditions like asthma or severe respiratory issues use Ацетилцистеин?

Official warnings state that caution is required for people with asthma or a history of bronchospasm (sudden airway narrowing). The product label advises that monitoring may be necessary, and that treatment discontinuation is described if bronchospasm occurs.

Q: Is Ацетилцистеин safe for people with a history of stomach ulcers or gastrointestinal bleeding?

Official precautions indicate that caution is required for patients with a history of peptic ulcer. This is due to a potential undesirable effect the medication might have on the gastric lining.

Q: What are specific cautions for elderly patients using Ацетилцистеин?

There is generally no specific information in regulatory summaries indicating that this medicine is expected to cause different side effects or problems in older people compared to younger adults.

Q: What conditions make a person ineligible to use Ацетилцистеин, according to regulatory data?

A prior history of hypersensitivity (severe allergic reaction) to the active drug substance is a condition that makes its use contraindicated. This is listed as a critical safety exclusion in official safety data.

Q: Why does the effervescent tablet form of Ацетилцистеин sometimes have a sulfurous smell?

Regulatory documents describe the presence of a mild sulphurous odor as a characteristic specific to the active substance itself. This smell does not indicate that the product has gone bad or that its quality has been compromised.

Q: What is the current scientific understanding of Ацетилцистеин's antioxidant properties?

The drug is known to be processed in the body into L-cysteine, which is then used as an essential precursor for glutathione (GSH). Glutathione is a protective molecule known for its antioxidant role in cells.

Q: Is it true that taking Ацетилцистеин requires drinking extra water?

Official information notes that abundant fluid intake is described as a factor that supports the drug’s intended mucolytic (mucus-thinning) effect. This is in addition to the water needed to dissolve effervescent forms.

Q: How long does Ацетилцистеин typically remain active in the body?

According to pharmacokinetic data, the amount of time required for half the dose to be eliminated from the body, known as the terminal elimination half-life, is approximately 2.27 hours in adults.

Q: What is the maximum duration of use described in the official product information?

For symptomatic treatment, official product information states that use longer than 8 to 10 days is generally discouraged unless under medical guidance. The duration of use is ultimately dependent on the underlying condition.

Q: How should I store Ацетилцистеин products to maintain their quality?

Official advice states that products in sachet or tablet form should typically be stored in their original package. This practice is necessary to protect the medication from moisture and help maintain its quality.

Q: Does Ацетилцистеин carry a risk of hypersensitivity reactions?

Yes, regulatory warnings confirm that serious hypersensitivity reactions (allergic-type reactions) have been reported. A history of such a reaction is listed as a contraindication for using the drug.

Q: What types of coughs is Ацетилцистеин generally used for?

The drug is indicated for symptoms of the respiratory system that involve the production of thick, viscous mucous and mucopurulent secretions. This is typically associated with productive coughs where mucus needs to be loosened.

Q: What happens in the body to break down and eliminate Ацетилцистеин?

After being absorbed, the drug is chemically changed in the body through a process called deacetylation to form L-cysteine. The resulting components are then primarily eliminated from the body through the urine and feces.

Advertisements

How should Ацетилцистеин be stored and disposed of?

Acetylcysteine: Storage and Disposal Requirements

Official regulatory guidelines for Acetylcysteine storage depend on the formulation.

Unopened vials of inhalation solution and oral forms must be stored at Controlled Room Temperature, generally not exceeding 30 C (86 F), and the product must not be frozen.

Post-Opening Stability is critical for the inhalation solution: any unused, undiluted portion must be stored in a refrigerator and discarded after 96 hours (4 days). Diluted solutions should be used freshly prepared. The container must be kept tightly closed and the medication must be stored out of the sight and reach of children.

Expired or unused Acetylcysteine must be disposed of in accordance with local, national, and international regulations, avoiding release into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ацетилцистеин found in:

A-Z Index: